IDIBAPS takes part in a 30 million euros project to develop new HIV vaccines
IDIBAPS takes part in the European HIV Vaccine Alliance (EHVA) to develop and evaluate new preventive and therapeutic vaccines. The European Commiss1
IDIBAPS takes part in the European HIV Vaccine Alliance (EHVA) to develop and evaluate new preventive and therapeutic vaccines. The European Commiss1
Researchers from Hospital Clínic, IDIBAPS, University of Barcelona (UB) and Mental Health Research Center (CIBERSAM), associated with Institute of1
IDIBAPS and Fundació Clínic take part in two of the ERIC (European Research Infrastructure Consortium) consortiums promoted by the European Commissio1
Researchers from the IIBB-CSIC and IDIBAPS have published an article in Oncotarget journal in which they have shown for the first time that diets en1
Dr. Jordi Bruix, Head of the hepatic Oncology Unit at Hospital Clínic de Barcelona, the Hepatic Oncology IDIBAPS research team, the Barcelona Clinic1
Researchers at Hospital Clínic and IDIBAPS lead a study in which a genomic test performed at the time of diagnosis in breast cancer is useful to iden1
Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies a1
The CIBERER (Networked Biomedical Research Center for Rare Diseases) has incorporated two new research groups, among them the Pathogenesis of autoim1
IDIBAPS researchers in collaboration with CIBERNED scientists identify for the first time, in a study published in EMBO Molecular Medicine, numerous1
IIBB-CSIC and IDIBAPS researchers have published an article in Scientific Reports describing the role of lysosomes in the damage caused by acetamino1